Axogen, Inc. publishes inaugural ESG Report
17 March 2022 - 10:00PM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today published its inaugural Environmental, Social, and
Governance (ESG) report highlighting the company’s corporate
responsibility and sustainability initiatives.
Axogen’s 2021 ESG Report showcases several of the company’s
recent ESG-related accomplishments, including: advancing our
innovation pipeline with new products in development and clinical
studies to expand our treatment algorithms; initiating programs in
Diversity, Equity, and Inclusion (DEI) and launching our first
Employee Resource Group to broaden our reach to talent; renovating
and developing facilities with improved sustainability measures;
improving data security; and supporting charitable organizations at
all locations.
“We believe this report highlights Axogen’s commitment to the
patients who drive our mission, the communities we serve, and to
our pursuit of advancing the science of nerve repair in ethical and
sustainable ways,” said Karen Zaderej, chairman, CEO, and president
of Axogen, Inc. “It complements our mission to improve quality of
life and is consistent with our Axogenic values of patient safety,
open and honest communication, and respect.”
Axogen’s 2021 ESG Report is inspired by the Sustainability
Accounting Standards Board’s (SASB) topics for disclosures.
Interested stakeholders can access the report on the company’s
website
at https://www.axogeninc.com/environmental-social-and-governance/.
About AxogenAxogen (AXGN) is the
leading company focused specifically on the science, development,
and commercialization of technologies for peripheral nerve
regeneration and repair. Axogen employees are passionate about
helping to restore peripheral nerve function and quality of life to
patients with physical damage or transection to peripheral nerves
by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral
nerve, or the inability to properly reconnect peripheral nerves,
can result in the loss of muscle or organ function, the loss of
sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard Nerve Connector®,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard Nerve
Protector®, a porcine submucosa ECM product used to wrap and
protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; and
Axoguard Nerve Cap®, a porcine submucosa ECM product used to
protect a peripheral nerve end and separate the nerve from the
surrounding environment to reduce the development of symptomatic or
painful neuroma. The Axogen portfolio of products is available in
the United States, Canada, the United Kingdom, South Korea, and
several other European and international countries.
Cautionary Statements Concerning Forward-Looking
StatementsThis press release contains “forward-looking”
statements as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations or predictions of future conditions, events, or
results based on various assumptions and management's estimates of
trends and economic factors in the markets in which we are active,
as well as our business plans. Words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” “projects,” “forecasts,” “continue,” “may,” “should,”
“will,” “goals,” and variations of such words and similar
expressions are intended to identify such forward-looking
statements. The forward-looking statements may include, without
limitation, statements related to the impact of COVID-19 on our
business, hospital staffing challenges and its impact on our
business, statements regarding our growth, our financial guidance
and performance, product development, product potential, regulatory
process and approvals, APC renovation timing and expense, sales
growth, product adoption, market awareness of our products,
anticipated capital requirements, including the potential of future
financings, data validation, expected clinical study enrollment,
timing and outcomes, our assessment of our internal controls over
financial reporting, our visibility at and sponsorship of
conferences and our educational events, regulatory process and
approvals and other factors, including legislative, regulatory,
political and economic developments not within our control. The
forward-looking statements are and will be subject to risks and
uncertainties, which may cause actual results to differ materially
from those expressed or implied in such forward-looking statements.
Forward-looking statements contained in this press release should
be evaluated together with the many uncertainties that affect our
business and our market, particularly those risk factors described
under Part I, Item 1A., “Risk Factors,” of our Annual Report on
Form 10-K for the most recently ended fiscal year, as well as other
risks and cautionary statements set forth in our filings with the
U.S. Securities and Exchange Commission. Forward-looking statements
are not a guarantee of future performance, and actual results may
differ materially from those projected. The forward-looking
statements are representative only as of the date they are made
and, except as required by applicable law, we assume no
responsibility to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
changed circumstances, or otherwise.
Contact:Axogen, Inc.Ed Joyce, Director, Investor
Relationsejoyce@axogeninc.comInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2023 to Mar 2024